Also known as: oral Wegovy
Semaglutide is a GLP-1 analogue marketed as OZEMPIC for type 2 diabetes and cardiovascular risk reduction in adults with established cardiovascular disease. It acts as a GLP-1 receptor agonist with glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, and minor delay of gastric emptying. U.S. initial approval in this label is 2017.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
SoSoThin.com launched a cash-pay semaglutide weight loss service on February 16, 2026. The company said the model offers fast access, transparent pricing, and a digital-first process without insurance delays.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07592546 |
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss |
NOT_YET_RECRUITING | PHASE4 |
| NCT07588984 |
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study |
NOT_YET_RECRUITING | |
| NCT07570810 |
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM |
NOT_YET_RECRUITING | NA |
| NCT07564414 |
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight |
NOT_YET_RECRUITING | PHASE3 |
| NCT07554417 |
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 |
NOT_YET_RECRUITING | PHASE4 |
| NCT07547878 |
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07527195 |
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) |
RECRUITING | PHASE1 |
| NCT07523633 |
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder |
RECRUITING | PHASE2 |
| NCT07511543 |
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07505303 |
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial |
NOT_YET_RECRUITING | PHASE2 |
